Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK109 + cadonilimab with or without paclitaxel as second-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma
CTR20211244Phase 2Active
- Sponsor
- Kangrong Dongfang
- Start
- Aug 2021
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pulocimab, cadonilimab, paclitaxel in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Kangrong Dongfang. Started Aug 2021; status: active.
02
Drugs
pulocimabcadonilimabpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20211244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211244.